What's new

EN
Banner
WHAT'S NEW
please select
AMS BioteQ Expands Patent Layout, Aims to Lead in New Antibiotic Drug Research(圖)
MEDIA
2021-11-19
AMS BioteQ Expands Patent Layout, Aims to Lead in New Antibiotic Drug Research
AMS BioteQ focuses its research and development efforts on three key stages: “novel compound development,” “patent in research and development technology,” and “new drug research and development.”
New Force of Novel Antimicrobial Dressings! AMS BioteQ Benefits Diabetic Wound Patients(圖)
MEDIA
2021-09-15
New Force of Novel Antimicrobial Dressings! AMS BioteQ Benefits Diabetic Wound Patients
Dressings play a crucial role in accelerating wound healing.
Kaohsiung Native's Development of Oral COVID-19 Medication, AMS BioteQ Progressing by Year-End(圖)
MEDIA
2021-08-31
Kaohsiung Native's Development of Oral COVID-19 Medication, AMS BioteQ Progressing by Year-End
In the research and development of oral medication for Wuhan pneumonia (novel coronavirus disease, COVID-19), the Taiwanese biotechnology industry is actively involved.
The Good News in the Development of New Drugs for COVID-19!(圖)
MEDIA
2021-07-27
The Good News in the Development of New Drugs for COVID-19!
The Good News in the Development of New Drugs for COVID-19! A New Type of Antibiotic Has Shown Effective Virus Suppression
Good News About Antiviral Drugs: Local Antibiotic Shows Nearly 100% Effectiveness in Inhibiting the Coronavirus.(圖)
MEDIA
2021-07-22
Good News About Antiviral Drugs: Local Antibiotic Shows Nearly 100% Effectiveness in Inhibiting the Coronavirus.
As the COVID-19 pandemic subsides, there’s positive news regarding the first antibiotic developed by a Taiwanese biotech company to inhibit the coronavirus.
Fighting COVID-19! Taiwan's Self-developed Two New Drugs Inhibit Virus with Near-Perfect Performance(圖)
MEDIA
2021-04-14
Fighting COVID-19! Taiwan's Self-developed Two New Drugs Inhibit Virus with Near-Perfect Performance
As the global COVID-19 pandemic continues, despite ongoing vaccination efforts in various countries, many risks and concerns remain.
1 2 3